Xeris Biopharma experimenta un aumento del 11.8% gracias a las esperanzas de ingresos récord y al impulso estratégico que genera la empresa.

Summary
• Xeris Biopharma (XERS) surges 15.05% intraday to $8.295, breaking above its 52-week high of $10.08
• Unaudited Q4 2025 results show $45M Recorlev® revenue and $292M total revenue, exceeding guidance
• CEO John Shannon highlights 'transformative 2025' and 2026 growth plans

Xeris Biopharma’s stock has erupted 15.05% in a single session, driven by blockbuster Q4 2025 results and bullish guidance. The biotech’s shares traded between $7.57 and $8.42, signaling a sharp reversal from its 52-week low of $3.14. With a robust balance sheet and a pipeline anchored by Recorlev® and XP-8121, the move reflects investor optimism about Xeris’ long-term growth trajectory.

Unprecedented Earnings Beat Ignites Xeris Biopharma’s 15% Surge
Xeris Biopharma’s 15.05% intraday rally stems from its unaudited Q4 2025 results, which revealed $45M in Recorlev® revenue and $292M in total revenue—surpassing its $285–$290M guidance. CEO John Shannon emphasized 'transformative 2025' momentum, with Recorlev® reaching 700 patients and Gvoke® revenue growing 13% YoY. The company also secured new patents for Recorlev® and XP-8121, reinforcing its IP moat. These catalysts, combined with a March 2, 2026, 2026 outlook release, have ignited speculative fervor.

Biotech Sector Volatility Amid Xeris’ Surge
While Xeris Biopharma’s 15.05% gain outperformed the broader biotech sector, sector leader Amgen (AMGN) fell 3.14% on profit-taking. The biotech sector remains polarized, with investors rotating into high-growth names like Xeris and out of large-cap peers. Xeris’ focus on orphan drugs and proprietary formulation platforms (XeriSol® and XeriJect®) positions it as a disruptor in niche markets, contrasting with Amgen’s diversified but slower-growth portfolio.

Options Playbook: High-Leverage Calls and Volatility-Driven Puts
• MACD: -0.0242 (bearish divergence), Signal Line: -0.04198 (negative), Histogram: 0.0177 (bullish crossover)
• RSI: 52.00 (neutral), Bollinger Bands: Upper $7.627, Middle $7.1945, Lower $6.7622
• 200D MA: $6.3785 (below current price), 30D MA: $7.0923 (support)

Xeris Biopharma’s technicals suggest a short-term bullish reversal after a long-term ranging pattern. Key levels to watch include the 200D MA ($6.38) as a critical support and the 52-week high ($10.08) as a resistance. The stock’s 2.01% turnover rate and 15.05% intraday gain indicate strong short-term momentum. Aggressive bulls may consider XERS20260116C7.5 (call) for a 181.82% price change potential, while volatility-driven traders could target XERS20260220C7.5 (call) with 100% price change and 64.63% implied volatility.

Top Option 1: XERS20260116C7.5
• Strike Price: $7.50, Expiration: 2026-01-16, IV: 24.94%, Leverage Ratio: 8.92%, Delta: 0.9958, Theta: -0.0346, Gamma: 0.0382, Turnover: 20,446
• IV (Implied Volatility): High volatility suggests strong market expectations
• Delta (Price Sensitivity): Near 1.0 indicates high sensitivity to price moves
• Theta (Time Decay): -0.0346 shows significant time erosion
• Gamma (Delta Sensitivity): 0.0382 implies moderate sensitivity to price changes
• Turnover: High liquidity ensures easy entry/exit
• Payoff: At 5% upside ($8.71), payoff = max(0, $8.71 - $7.50) = $1.21 per share
• Why it stands out: High leverage ratio and IV make this call ideal for a short-term rally.

Top Option 2: XERS20260220C7.5
• Strike Price: $7.50, Expiration: 2026-02-20, IV: 64.63%, Leverage Ratio: 6.92%, Delta: 0.7211, Theta: -0.0116, Gamma: 0.1804, Turnover: 10,308
• IV (Implied Volatility): Mid-to-high range suggests balanced risk/reward
• Delta (Price Sensitivity): 0.7211 indicates moderate sensitivity to price moves
• Theta (Time Decay): -0.0116 shows moderate time erosion
• Gamma (Delta Sensitivity): 0.1804 implies strong sensitivity to price changes
• Turnover: High liquidity ensures easy entry/exit
• Payoff: At 5% upside ($8.71), payoff = max(0, $8.71 - $7.50) = $1.21 per share
• Why it stands out: High gamma and IV make this call responsive to price swings, ideal for a volatile biotech play.

Hook: Aggressive bulls may consider XERS20260116C7.5 into a bounce above $8.42.

Backtest Xeris Biopharma Stock Performance
The backtest of XERS's performance following a 15% intraday surge from 2022 to the present indicates positive short-to-medium-term gains. The 3-Day win rate is 52.76%, the 10-Day win rate is 54.97%, and the 30-Day win rate is 60.93%, suggesting that XERS tends to experience gains even in the immediate aftermath of such a significant event. The maximum return observed was 11.69% over 30 days, indicating that while the gains are not always immediate, they can be substantial in the following weeks.

Xeris Biopharma’s 15% Rally: A Catalyst-Driven Buy or Sell-Off Setup?
Xeris Biopharma’s 15.05% surge reflects strong Q4 2025 results and a bullish 2026 outlook, but technicals show a short-term bearish trend amid long-term ranging. The stock’s 200D MA at $6.38 acts as a critical support, while the 52-week high of $10.08 remains a distant target. Investors should monitor the March 2, 2026, guidance release and IP developments for XP-8121. Meanwhile, sector leader Amgen (AMGN) fell 3.14%, highlighting biotech sector rotation. Action: Watch for a breakdown below $7.57 or a breakout above $8.42 to confirm the next move.